Edward Abrahams, Ph.D., is
president of the Personalized Medicine Coalition (PMC). Representing
innovators, scientists, patients, providers and payers, PMC promotes the
understanding and adoption of personalized medicine concepts, services and
products for the benefit of patients and the health system. It has grown from
its original 18 founding members in 2004 to over 225 today.
Previously Dr. Abrahams was
Executive Director of the Pennsylvania Biotechnology Association, where he
spearheaded the successful effort that led to the Commonwealth of
Pennsylvania’s investment of $200 million to commercialize biotechnology in
the state. Earlier he had been Assistant Vice President for Federal Relations
at the University of Pennsylvania and held a senior administrative position
at Brown University.
Dr. Abrahams worked for seven
years for the U.S. Congress, including as a legislative assistant to Senator
Lloyd Bentsen, an economist for the Joint Economic Committee under the
chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow
for Representative Edward J. Markey.
The author of numerous
essays, Dr. Abrahams serves on the editorial board of Personalized Medicine
and has also taught history and public policy at Brown University and the
University of Pennsylvania.
Dr. William (Bill) S. Dalton
is President, Chief Executive Officer and Center Director of Moffitt Cancer
Center and Research Institute, an NCI-Designated Comprehensive Cancer Center,
and serves as Board Chairman of M2Gen, a national biotechnology subsidiary of
Moffitt Cancer Center. A nationally renowned cancer researcher, physician and
health policy expert, Dr. Dalton has dedicated his career to the study and
development of the most effective approaches to cancer research and care. For
his leadership in the development of personalized cancer care and
patient-centered outcomes research, Dr. Dalton was recognized as the 2010
recipient of the Personalized Medicine Coalition’s Leadership in Personalized
Dr. Dalton currently serves as
the President-Elect of the Association of American Cancer Institutes and is
Chair of the Science Policy & Legislative Affairs Committee of the
American Association for Cancer Research. In addition, Dr. Dalton serves on the
Institute of Medicine’s, National Cancer Policy Forum and served on the
National Cancer Institute (NCI) Board of Scientific Advisors as well as
multiple scientific advisory boards at cancer centers and research
foundations across the U.S.
Dr. Eck is Vice President and Global Head
of Oncology Medical Sciences at Astellas Pharma Global Development
(Headquartered in Northbrook, IL). He is directly responsible for the
oversight of oncology drug development plans. Much of this work is focused on
special cancer populations for which unique biology enables the development
of personalized cancer therapies. Dr. Eck previously served as Vice
President, Translational Medicine & Pharmacogenomics at Eli Lilly and
Company (2007-2011) where he was responsible for the clinical pharmacology
components of drug development including both early phase clinical studies
and late stage drug development studies. His group also developed the
biomarkers and companion diagnostics needed for effective decision-making and
for tailoring therapeutics to the right patient population. Prior to Joining
Lilly, Dr. Eck served in a variety of drug development leadership roles at
Pfizer, Inc (2002-2007).
Dr. Eck is a board certified
Hematologist/Oncologist with broad drug development experience in Oncology
and Neuroscience. He is a Fellow of the American Association for the
Advancement of Science (Pharmaceutical Sciences). He serves on the Scientific
Advisory Board of the ACGT Foundation (which supports academic cancer
research), and is a member of the Executive Committee of the Fairbanks
Institute (an institution dedicated to developing data banks to enable
personalized medicine). He also serves on the Advisory Board of the Keck
Graduate School (Claremont, CA).
D. Stafford O'Kelly, retired,
was formerly President of Abbott Molecular.
He served in this role from 2007-2012.
Mr. O'Kelly joined Abbott in
1984 and served in various management positions. These included Vice
President, Latin America/Canada Operations; Division Vice President Finance,
Abbott International, Division; Vice
President and Controller, Ross Products Division (now Abbott Nutrition); and
Vice President Finance, TAP
Mr. O'Kelly serves on the
boards of Youth Conservation Corps, Inc., and the Clara Abbott Foundation.
He has a bachelor's degree in
engineering and MBA from Trinity College in Dublin, Ireland.
Amy P. Abernethy, MD is
Associate Professor of Medicine, Duke University School of Medicine;
Director, Duke Center for Learning Health Care; Senior Fellow with the Duke
Center for Clinical Health Policy Research; faculty in the Duke Clinical
Research Institute; and, an active clinician in both outpatient and inpatient
oncology. Dr. Abernethy was also recently appointed to the National Cancer
Policy Forum with the Institute of Medicine.
A NIH and AHRQ funded
investigator with a substantial portfolio focused on comparative
effectiveness research (CER) and patient reported outcomes in cancer, Dr.
Abernethy founded and directs the Duke Cancer Care Research Program (DCCRP).
DCCRP is developing a new model of combined clinical/research inquiry in
oncology, and IT-based methods to support it, in order to facilitate
personalized CER. This model, the “rapid learning cancer clinic,” uses
electronic patient-reported outcomes as the foundation for a real-time linked
data system designed to facilitate evidence-based, individualized care as an
integral component of routine cancer care in the 21st century. Approaches
fundamentally rely on principles of data interoperability and sharing, and
Dr. Abernethy is leading Duke’s efforts to create a transferable model of a
learning healthcare system.
Brian Munroe is the founder
and the immediate Past-President of the Personalized Medicine Coalition
(PMC). He currently serves as the
Chairman of the PMC Public Policy Committee and on the Executive Committee of
the PMC Board of Directors.
Brian is a twenty year veteran
of health care public policy, advocacy, and communications. His areas of expertise are in FDA
legislation and regulations, Medicare and Medicaid reimbursement, federal and
state tax policy, and the development of government policies to advance
Brian has created successful, stand alone Government Affairs
Departments from scratch at: SmithKline Beecham, Millennium Pharmaceuticals, and Endo
Pharmaceuticals. He is currently the
Vice President in charge of Washington office, the Public Policy group, State
Government Relations and, the Political Action Committee at Endo. He also serves on Endo’s Executive
Brian’s breadth in health care
policy stretches across pharma /biotech, home health care, diagnostics,
medical devices, clinical laboratories, and health care payors. His geographical responsibilities have
included the fifty states, the Federal government and Congress, and for a
short time the European Union and member countries.
Brian began his career in
Washington, D.C. working for United States Senator Alan Cranston (D-CA).
Brian currently lives in the
Washington, D.C. area with his wife Vicky and their four children.
Wayne is a Distinguished
Fellow at the Center for Biomedical Innovation at MIT working on health care
strategy and policy issues related to science and medicine, a member of the
Ethics and Systems Medicine Program at Georgetown University and Chairman of
the board of directors of the Personalized Medicine Coalition. He is also VP Strategic Consulting at Fuld
& Company focusing on strategic simulations in health care, Chief
Scientific Advisor at Expertech focusing on strategic futuring for Air Force
Medical Systems, and Chief Applications Officer for SciTech Strategies
focusing on scientific competency and capacity development for academia and
industry. He is a former Director of
External Relations for Personalized Healthcare and Evidence-based Medicine
(EBM) as part of External Medical Relations at AstraZeneca where he had
responsibility for long-range external relations strategy and policy
development. Prior to that role, he
was involved in long-term strategy development for the AstraZeneca Discovery,
Development, and US Commercial divisions, and created and ran strategic
intelligence units at both AstraZeneca and SmithKIine Beecham
Pharmaceuticals. He is a former
President of SCIP (Society of Competitive Intelligence Professionals) and has
received the SCIP Fellows Award and Lifetime Achievement Award in
Intelligence from Frost and Sullivan.
Wayne is active on strategy and advisory boards of several
organizations including the IOM, IBM Life Sciences, and Hewlett-Packard Life
Sciences. He has presented at numerous
forums on aspects of personalized health care, evidence-based medicine, new
development paradigms, and strategy development. He holds a B.S. in Biology from MIT, a
Ph.D. in Cell and Molecular Biology from Boston University, and received
post-doctoral training in Cancer and Radiation Biology at the University of
Rochester. Wayne lives in Malvern,
Pa., is married with two college-age children, and enjoys teaching martial
arts (Tang Soo Do), restoring antique/classic Fords, and aviation history.